Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Pass Below 200-Day Moving Average of $7.01

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $7.01 and traded as low as $4.19. Eagle Pharmaceuticals shares last traded at $4.24, with a volume of 130,155 shares traded.

Eagle Pharmaceuticals Trading Down 1.9 %

The company has a 50-day moving average of $5.40 and a 200-day moving average of $6.94. The company has a market capitalization of $54.04 million, a price-to-earnings ratio of 3.53 and a beta of 0.41.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Brandes Investment Partners LP increased its holdings in shares of Eagle Pharmaceuticals by 34.9% in the third quarter. Brandes Investment Partners LP now owns 1,134,363 shares of the specialty pharmaceutical company’s stock valued at $17,889,000 after purchasing an additional 293,276 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Eagle Pharmaceuticals by 25.0% in the third quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the specialty pharmaceutical company’s stock worth $7,885,000 after buying an additional 100,000 shares during the last quarter. Smith Graham & Co. Investment Advisors LP boosted its stake in shares of Eagle Pharmaceuticals by 1.4% in the third quarter. Smith Graham & Co. Investment Advisors LP now owns 273,099 shares of the specialty pharmaceutical company’s stock worth $4,307,000 after buying an additional 3,648 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Eagle Pharmaceuticals by 5.5% in the third quarter. Acadian Asset Management LLC now owns 236,902 shares of the specialty pharmaceutical company’s stock worth $3,733,000 after buying an additional 12,326 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Eagle Pharmaceuticals by 66.5% during the third quarter. Assenagon Asset Management S.A. now owns 217,668 shares of the specialty pharmaceutical company’s stock worth $3,433,000 after purchasing an additional 86,917 shares in the last quarter. 85.36% of the stock is owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.